With a market capitalization (market cap) of $4.75B — a measure of how much the company is worth — Edgewise Therapeutics, Inc. is the 1464th most valuable company in Healthcare as of August 18, 2026. Shares trade at $44.11, up +0.16% on the day.
of 2,587
price ÷ annual EPS
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
Visit websiteAs of August 18, 2026, Edgewise Therapeutics, Inc. (EWTX) is worth $4.75B — this is its market capitalization, the total value of all its outstanding shares.
Edgewise Therapeutics, Inc.’s market cap is $4.75B, which ranks it #1464 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
Edgewise Therapeutics, Inc. (EWTX) shares trade at $44.11, up 0.16% on the day, as of August 18, 2026.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2025